Trials / Terminated
TerminatedNCT06568302
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
A Global Open-label Extension Study to Observe the Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- ApcinteX Ltd · Industry
- Sex
- Male
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with hemophilia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SerpinPC | Administered as SC injection. |
Timeline
- Start date
- 2024-07-11
- Primary completion
- 2025-01-29
- Completion
- 2025-01-29
- First posted
- 2024-08-23
- Last updated
- 2025-02-10
Locations
2 sites across 2 countries: Georgia, Moldova
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06568302. Inclusion in this directory is not an endorsement.